Avita Medical Ltd. (AVMXY: OTCQX International) | Avita Medical Highlights ReCell® Findings Published in Journal of Cranio-Maxillo-Facial Surgery


Avita Medical Highlights ReCell® Findings Published in Journal of Cranio-Maxillo-Facial Surgery

Oct 20, 2015

OTC Disclosure News Service

Northridge, CA and Cambridge, UK

Validates ReCell® as treatment for improving
aesthetic outcomes in patients who had free flap transfers to repair complex
facial defects after cancer resection

Medical Ltd. (ASX: AVH),
a medical device company specializing in the treatment of wounds and skin
defects, today announced results from a series of cases using ReCell® showing
clinically significant improvements in the aesthetic outcomes of repaired complex
facial defects resulting from surgical removal of non-melanocytic skin cancers
(NMSC).  The report was published online in
the Journal of Cranio-Maxillo-Facial Surgery, and
is currently in press for publication in an upcoming print issue of the


Surgeons often face challenges balancing functional
needs with patient’s aesthetic standards when repairing the facial region
following surgical removal of NMSC, which frequently results in extensive
tissue loss requiring a plastic surgery technique called a free flap.  Harvesting ‘remote free flaps’ of skin along
with subcutaneous tissue from other parts of the body and transferring them to
the recipient region often results in mismatched skin color, volume and
elasticity, all of which dramatically impair the facial appearance.


In the series, titled “Surface-optimized free flaps for complex facial
defects after skin cancer
” by
Kesting, M.R. et al,1
researchers identified a series of four patients for whom NMSC defects were reconstructed
using remote free flaps, followed by secondary correction of the flap surface by
de-epithelialization and application of
Regenerative Epithelial
Suspension (RES™) produced using ReCell®.
They found that the secondary procedure including RES™ improved the pigment,
volume, texture and elasticity of free flaps in the facial region. Furthermore,
all treated flap areas healed uneventfully and by 12 months after the secondary
treatment, all patients presented with sufficient color and volumetric matching
of the flaps and with healed donor sites.


“This series represents one
of the many real-world aesthetic applications of our unique ReCell® technology,”
commented Adam Kelliher, Chief Executive Officer of Avita Medical. “Cancer in
the facial region can be severely debilitating and its removal can cause
considerable loss of tissue, making reconstruction a delicate procedure. Positive
outcomes from this study, demonstrating treatment using ReCell® significantly
improves aesthetic outcomes
of repaired complex facial defects, hold substantial promise for patients undergoing
NMSC tumor removal and indicate the potential of RES™ to aesthetically improve
a variety of other surgical reconstructions.”

Avita Medical’s proprietary ReCell®
technology allows
physicians to quickly create, at point of care,
Regenerative Epithelial
Suspension (RES™) using a small sample of the
patient’s skin that can then be applied to the skin defect as treatment. The
devices are typically used in conjunction with traditional methods.



1. Kesting MR, et al.,
Surface-optimized free flaps for complex facial defects after skin cancer,
Journal of CranioMaxillo-Facial

Surgery (2015), http://dx.doi.org/10.1016/j.jcms.2015.08.010



ReCell® is Avita
Medical’s unique proprietary technology that enables a clinician to rapidly
create, at point of care in approximately 30 minutes, Regenerative Epithelial
Suspension (RES™) using a small sample of the patient’s skin. RES™ is an
autologous suspension comprising the cells and wound healing factors necessary
to regenerate natural, healthy skin. RES™ has a broad range of applications and
can be used to restart healing in unresponsive wounds, to repair burns using
less donor skin yet with improved functional and aesthetic outcomes, and to
restore pigmentation and improve cosmesis of damaged skin.



Avita Medical develops
and distributes regenerative products for the treatment of a broad range of
wounds, scars and skin defects. Avita’s patented and proprietary collection and
application technology provides innovative treatment solutions derived from a
patient’s own skin. The Company’s lead product, ReCell®, is used in the
treatment of a wide variety of burns, plastic, reconstructive and cosmetic
procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in
Australia, and CFDA‐cleared in China. In the United States, ReCell® is an
investigational device limited by federal law to investigational use. A pivotal
U.S. trial is underway, with patient enrollment completion anticipated by the
end of 2015. To learn more, visit www.avitamedical.com.



For Further Information:


Avita Medical Ltd

Adam Kelliher

Chief Executive Officer

Phone: +44 (0) 1763 269 772



Medical Ltd

Tim Rooney

Chief Financial Officer

Phone: + 1 (818) 356-9400



Avita Medical Ltd

Gabriel Chiappini

Company Secretary

Phone +61(0) 8 9474 7738




The Ruth Group

Lee Roth, Investor Relations

Kirsten Thomas, Public Relations

Phone: +1 (646) 536-7012 / +1 (508) 280-6592


/ kthomas@theruthgroup.com



Monsoon Communications

Rudi Michelson

Investor Relations / PR

Phone: +61 3 9620 3333








This release includes additional documents. Select the link(s) below to view.

Avita – ReCell Journal of CMF Surgery Publication Release FINAL 20151020.pdf

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply